Unlearn.AI

Research

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Cell and Gene Therapy

Adicet Bio, Inc. | September 06, 2022

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Cell and Gene Therapy, Medical

Be The Match BioTherapies® | January 18, 2023

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to ...

The World News Monitor | April 08, 2020

• 3 Blue-Chip Biotech Stocks Hitting New Highs. A basket of biotech stocks have surged to new highs in recent weeks, lifting the iShares Nasdaq Biotechnology Index Fund ETF (IBB) within 15 points of 2019 resistance.The stock posted an all-time high at $128 in Tuesday’s session, lifting above 2019 resistance at $122. Price action into the second half of 2019 carved a long series of lower highs and lower lows, dropping the stock to a six-year low....